Boehringer Ingelheim and Zealand Pharma Announce Promising Results for MASH Treatment Drug

Boehringer Ingelheim and Zealand Pharma Announce Promising Results for MASH Treatment Drug

Viktorija Petrović
2 min read

Boehringer Ingelheim and Zealand Pharma Announce Promising Results for MASH Treatment Drug

Boehringer Ingelheim and Zealand Pharma have revealed positive outcomes in the treatment of liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) using their GLP-1/glucagon receptor dual agonist, survodutide. According to data from a Phase II trial, 52.3% of patients demonstrated improvements in fibrosis, compared to 25.8% in the placebo group. Additionally, 83% of adults showed significant improvement in MASH, following the trial's initial announcement in February 2024. These detailed results were presented at the European Association for the Study of the Liver Congress 2024 and published in the New England Journal of Medicine. Boehringer is now moving survodutide into Phase III trials for the treatment of obesity, following encouraging results from preceding studies.

Key Takeaways

  • Survodutide, a GLP-1/glucagon receptor dual agonist, has shown significant promise in improving liver fibrosis in MASH patients.
  • 52.3% of patients with different stages of fibrosis experienced improvements with survodutide, in contrast to 25.8% with placebo.
  • The drug also demonstrated effectiveness in mitigating liver scarring without exacerbating MASH in 64.5% of patients with moderate or advanced fibrosis.
  • Boehringer's and Zealand's survodutide is in direct competition with Eli Lilly's Mounjaro in the treatment of MASH-related fibrosis.
  • Positive Phase II results have propelled Boehringer's plans to progress survodutide into Phase III trials.


The successful Phase II trial of survodutide represents a significant milestone in addressing liver fibrosis within MASH patients. This development has the potential to reshuffle the treatment landscape, affecting competitors such as Eli Lilly. In the short term, the findings bolster Boehringer's standing in the MASH treatment market and advocate for increased investment in Phase III trials. In the long run, the confirmation of these results in Phase III trials could instigate a paradigm shift in MASH management, benefiting patients and potentially influencing the competitive dynamics of the pharmaceutical industry in this specialty.

Did You Know?

  • Metabolic Dysfunction-Associated Steatohepatitis (MASH): A progressive form of non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation and damage caused by fat accumulation. MASH can lead to severe scarring (fibrosis) and cirrhosis of the liver.
  • GLP-1/glucagon Receptor Dual Agonist: A type of drug that activates both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. This dual action helps in managing glucose levels, reducing appetite, and potentially improving liver health by reducing fat accumulation and inflammation in the liver.
  • Phase II and Phase III Clinical Trials: Phase II trials evaluate the drug's effectiveness for a specific indication and assess common short-term side effects and risks. Phase III trials further evaluate its efficacy and safety in a larger population and under different conditions, often comparing it to standard or equivalent treatments. These phases are pivotal in the drug approval process by regulatory authorities.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings